Product Description
ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15468604/)
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company Founding Year: 1888
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Renal Cell Carcinoma|Sarcoma|Non-Small-Cell Lung Cancer|Melanoma|Head and Neck Cancer
Phase 1: Skin Cancer|Vascular Cancer|Myocardial Infarction|Breast Cancer|Anemia|Anorexia|Small Cell Lung Cancer|Ovarian Cancer|Glioma|Headache|Kidney Diseases|Diarrhea|Constipation|Dyspnea|Edema|Colorectal Cancer|Angina, Stable|Dizziness|Hypertension, Renal|Asthenia|Angina, Unstable|Low Back Pain|Chest Pain|Insomnia|Abdominal Pain|Brain Cancer|Ischemic Attack, Transient|Peripheral Arterial Disease|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00586092 |
Pro00008797 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Low Back Pain|Asthenia|Angina, Unstable|Angina, Stable|Insomnia|Peripheral Arterial Disease|Vascular Cancer|Breast Cancer|Ischemic Attack, Transient|Colorectal Cancer|Edema|Diarrhea|Kidney Diseases|Chest Pain|Anemia|Anorexia|Small Cell Lung Cancer|Ovarian Cancer|Headache|Skin Cancer|Glioma|Dyspnea|Constipation|Myocardial Infarction|Abdominal Pain|Dizziness|Hypertension, Renal |
2013-02-01 |
2019-03-22 |
Treatments |
|
NCT00584883 |
UAB 0327 | P1 |
Completed |
Brain Cancer |
2008-07-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00113334 |
NCT00113334 | P2 |
Completed |
Head and Neck Cancer |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT00602199 |
CDR0000582475 | P2 |
Completed |
Melanoma |
2005-06-01 |
2019-03-18 |
Treatments |
|
NCT00061672 |
M02-457 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
2019-03-21 |
Treatments |
|
NCT00073125 |
M02-428 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
Treatments |
|
NCT00061659 |
M02-534 | P2 |
Completed |
Sarcoma |
None |
2019-03-21 |
Treatments |
|
NCT00061646 |
M02-429 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
None |
2019-03-21 |
Treatments |